title: Outcomes of kidney transplantation in patients with systemic lupus erythematosus: a single-center study.
abstract: INTRODUCTION. This study aimed to compare outcomes of kidney transplantation in patients with systemic lupus erythematosus (SLE) and a matched control group of non-SLE kidney recipients. MATERIALS AND METHODS. In a case-control study, 33 patients with kidney transplantation due to end-stage renal disease caused by SLE were matched to a control group consisted of 33 non-SLE patients who had been transplanted during the same period of time in our center. The clinical characteristics, complications, and patient and graft survival were compared between the two groups. RESULTS. In each group, 12 patients (36.4%) received a kidney from a deceased donor, 15 (45.4%) from a living unrelated donor, and 6 (18.2%) from a living related donor. There was no significant difference between the outcome in SLE patients and duration of dialysis before transplantation. The mean duration of hospital stay was 23.4 ± 18.1 days in the SLE group, while it was 13.0 ± 7.3 days in the controls (P = .006). One-year graft survival was 79.0% in patients with SLE and 90.9% in non-SLE patients (P = .17). One-year patient survival was 93.9% in patients with SLE versus 81.8% in the controls (P = .26). Nine patients in the SLE group versus 11 patients in the control group developed posttransplant complications (P = .59). CONCLUSIONS. Although hospital stay after transplantation was longer in the SLE kidney recipients than controls, safety of kidney transplantation was comparable. Graft failure in the SLE patients was not significantly different between patients with different sources of kidneys.
authors.affiliation: Shiraz Organ Transplant Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Iran.
authors.forename: Jamshid
authors.initials: J
authors.lastname: Roozbeh
authors.forename: Ahad
authors.initials: A
authors.lastname: Eshraghian
authors.forename: Ghanbarali
authors.initials: G
authors.lastname: Raeesjalali
authors.forename: Saeed
authors.initials: S
authors.lastname: Behzadi
authors.forename: Saman
authors.initials: S
authors.lastname: Nikeghbalian
authors.forename: Mohammad Mehdi
authors.initials: MM
authors.lastname: Sagheb
authors.forename: Mehdi
authors.initials: M
authors.lastname: Salehipour
authors.forename: Ali
authors.initials: A
authors.lastname: Bahador
authors.forename: Heshmatollah
authors.initials: H
authors.lastname: Salahi
authors.forename: Seyed Ali
authors.initials: SA
authors.lastname: Malekhosseini
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D005260:Female; D006085:Graft Survival; D006801:Humans; D007676:Kidney Failure, Chronic / Q000209:etiology* / Q000601:surgery*; D016030:Kidney Transplantation; D007902:Length of Stay / Q000706:statistics & numerical data; D008180:Lupus Erythematosus, Systemic / Q000150:complications*; D008297:Male; D015996:Survival Rate; D016896:Treatment Outcome